This preclinical data highlights that BGB324, a first-in-class, highly selective small molecule inhibitor of the Axl receptor tyrosine kinase
, used in combination with immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1) in mouse carcinoma models showed enhanced tumour clearance, survival and tumour infiltration of cytotoxic T lymphocytes compared with checkpoint inhibition alone.
MGCD265 Phase 1/1b Study, Expansion Cohort: MGCD265 is an inhibitor of the MET and Axl receptor tyrosine kinase
pathways which, when mutated, are drivers of tumor growth.
BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase
, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 - June 2, 2015.
BGB324 is the only selective Axl receptor tyrosine kinase
inhibitor in clinical development to target tumor epithelial-mesenchymal transition (EMT) and has a potential application as a novel treatment for drug-resistant solid and hematological cancers, including non-small cell lung cancer and acute myeloid leukemia.
Presentation Date: Tuesday, March 17, 2009 Session: Poster Session 2 Poster Number: 206 Poster Title: Suppression of Breast Cancer Metastasis by R428, a Novel Small Molecule Inhibitor of the Axl Receptor Tyrosine Kinase
About Rigel (http://www.
Date: Thursday, January 17 Poster: Session 2, #220 Title: Suppression of angiogenesis and tumor growth by novel small molecule inhibitors of the Axl receptor tyrosine kinase
Keystone Symposia: Viral Immunity -- Keystone, CO Date: Wednesday, January 23 Poster: Session 3, #335 Title: Inhibition of HIV replication by pharmacologic restoration of Apobec3G antiviral function
They will highlight drug discovery efforts focused on significant cancer targets including Axl receptor tyrosine kinase
(Axl), Polo- like kinase 1 (PLK1) and Janus tyrosine kinase 2 (JAK2).
One of the presentations is entitled, "Small Molecule Inhibitors of the Axl Receptor Tyrosine Kinase
as Therapeutics for Angiogenesis and Tumor Growth".
February 4-9, 2007: Keystone Symposia: Ubiquitin and Signaling in Big Sky, Montana Time: Wednesday, February 7 Poster Session: Session 3 Poster Number: 303 Title: Ubiquitin chain synthesis and substrate modification by the UBC13-UEV ubiquitin-conjugating enzyme February 11-16, 2007: Gordon Research Conference: Vascular Cell Biology in Ventura, California Time: February 12-15, 4-6pm Title: Small molecule inhibitors of the Axl receptor tyrosine kinase
as therapeutics for cardiovascular diseases and tumors About Rigel (http://www.
Interim Update on the Ongoing MGCD265 Phase 1b Expansion Cohort MGCD265 is an inhibitor of the MET and Axl receptor tyrosine kinases
which, when mutated or amplified, can be drivers of tumor growth.